What do long-term data from the VIALE-A trial tell us about treatment with azacitidine plus venetoclax?

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub was pleased to speak to Courtney DiNardo, MD Anderson Cancer Center, Houston, US. We asked, What do long-term data from the VIALE-A trial tell us about treatment with azacitidine plus venetoclax?

DiNardo discusses findings from the long-term follow-up of the VIALE-A trial presented at ASH, including the continued improved overall survival of patients treated with azacitidine plus venetoclax compared with azacitidine alone. Covering topics such as prognostic mutational features and European LeukemiaNet risk groups, DiNardo comments on how use of this combination therapy impacts patients with acute myeloid leukemia in the long term.